Torren Management’s Relay Therapeutics RLAY Stock Holding History

Torren Management’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,544	Closed	-$30K	–	1358
2025 Q4	$30K	Buy	+3,544	New	+$25.3K	0.02%	474

Other funds holding RLAY

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Torren Management's RLAY Position: Q1 2026 in Review

Torren Management sold out of Relay Therapeutics (RLAY) in Q1 2026, closing a stake of 3,544 shares — an estimated $30K sold.

Torren Management first reported a position in RLAY in Q4 2025 and held it in 1 quarter. The position peaked at $30K in Q4 2025. 243 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

Torren Management reported no remaining Relay Therapeutics position as of Q1 2026 after selling out during the quarter.
Torren Management sold 3,544 Relay Therapeutics shares in Q1 2026, an estimated $30K.
Torren Management first reported a position in Relay Therapeutics in Q4 2025 and held it in 1 quarter.
Torren Management's Relay Therapeutics position peaked at $30K in Q4 2025.
243 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.